loading...| Preferred Name |
Arsenic Trioxide |
|
| Synonyms |
arsenic trioxide Arsenic Trioxide Arsenic trioxide Arsenous Acid Anhydride Arsenic (III) Oxide Arsenous Oxide White Arsenic Arsenous Acid Arsenic Sesquioxide ARSENIC TRIOXIDE ATO Trisenox |
|
| Definitions |
A small-molecule arsenic compound with antineoplastic activity. The mechanism of action of arsenic trioxide is not completely understood. This agent causes damage to or degradation of the promyelocytic leukemia protein/retinoic acid receptor-alpha (PML/RARa) fusion protein; induces apoptosis in acute promyelocytic leukemia (APL) cells and in many other tumor cell types; promotes cell differentiation and suppresses cell proliferation in many different tumor cell types; and is pro-angiogenic. (NCI04) |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1005 |
|
| Accepted_Therapeutic_Use_For |
Myelodysplastic syndrome; multiple myeloma; chronic myeloid leukemia; acute myelocytic leukemia |
|
| ALT_DEFINITION |
A drug used to treat acute promyelocytic leukemia (APL) that has not gotten better or that has come back after treatment with other anticancer drugs. It is also being studied in the treatment of other types of cancer. |
|
| CAS_Registry |
1327-53-3 |
|
| CHEBI_ID |
CHEBI:30621 |
|
| Chemical_Formula |
As2O3 |
|
| code |
C1005 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173234 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C174019 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
CTRP FDA GDC HemOnc PCDC |
|
| DEFINITION |
A small-molecule arsenic compound with antineoplastic activity. The mechanism of action of arsenic trioxide is not completely understood. This agent causes damage to or degradation of the promyelocytic leukemia protein/retinoic acid receptor-alpha (PML/RARa) fusion protein; induces apoptosis in acute promyelocytic leukemia (APL) cells and in many other tumor cell types; promotes cell differentiation and suppresses cell proliferation in many different tumor cell types; and is pro-angiogenic. (NCI04) |
|
| Display_Name |
Arsenic Trioxide |
|
| FDA_UNII_Code |
S7V92P67HO |
|
| FULL_SYN |
arsenic trioxide Arsenic Trioxide Arsenic trioxide Arsenous Acid Anhydride Arsenic (III) Oxide Arsenous Oxide White Arsenic Arsenous Acid Arsenic Sesquioxide ARSENIC TRIOXIDE ATO Trisenox |
|
| Has_Target | ||
| Is_PCDC_AML_Authorized_Value_For_Variable | ||
| Is_Value_For_GDC_Property | ||
| label |
Arsenic Trioxide |
|
| Legacy Concept Name |
Arsenic_Trioxide |
|
| Maps_To |
Arsenic Trioxide |
|
| NCI_Drug_Dictionary_ID |
43067 |
|
| NSC Number |
706363 |
|
| PDQ_Closed_Trial_Search_ID |
43067 |
|
| PDQ_Open_Trial_Search_ID |
43067 |
|
| Preferred_Name |
Arsenic Trioxide |
|
| prefixIRI |
Thesaurus:C1005 |
|
| Semantic_Type |
Pharmacologic Substance Inorganic Chemical |
|
| UMLS_CUI |
C0052416 |
|
| subClassOf |